免疫|当下免疫治疗时代疾病进展后的治疗选择( 七 )


22. Klemen ND, Wang M, Feingold PL, et al. Patterns of failureafter immunotherapy with checkpoint inhibitors predict durable progression-freesurvival after local therapy for metastatic melanoma. J Immunother Cancer 2019;7: 196.
23. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124: 687–95.
24. Fujita K, Uchida N, Yamamoto Y, et al. Retreatment withanti-PD-L1 antibody in advanced non-small cell lung cancer previously treatedwith anti-PD-1 antibodies. Anticancer Res 2019; 39: 3917–21.
25. Longoria TC, Tewari KS. Evaluation of the pharmacokinetics andmetabolism of pembrolizumab in the treatment of melanoma. Expert Opin DrugMetab Toxicol 2016; 12: 1247–53.
26. Schvartsman G, Peng SA, Bis G, et al. Response rates tosingle-agent chemotherapy after exposure to immune checkpoint inhibitors inadvanced non-small cell lung cancer. Lung Cancer 2017; 112: 90–95.
27. Schvartsman G, Peng SA, Bis G, et al. Response rates tosingle-agent chemotherapy after exposure to immune checkpoint inhibitors inadvanced non-small cell lung cancer. Lung Cancer 2017; 112: 90–95.

推荐阅读